Core Insights - BioMark Diagnostics has published a significant study on using metabolomics and machine learning to identify biomarkers for pulmonary neuroendocrine neoplasms (NENs), which could enhance early diagnosis and monitoring of this type of cancer [2][3]. Company Overview - BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests aimed at early cancer detection, utilizing metabolomics and machine learning algorithms [9]. - The company's technology allows for a non-invasive method to detect NENs and has shown clinical utility in early detection of other difficult-to-detect cancers, such as lung cancer [4]. Research Findings - The study analyzed 153 metabolites from a cohort of 657 samples, including NEN patients, healthy controls, and individuals with non-small cell lung cancers (NSCLCs), revealing significant metabolic alterations associated with NENs [3]. - These findings contribute to the understanding of cancer metabolism and its clinical applications, potentially leading to new biomarkers for early detection and improved management of lung NENs [3]. Industry Context - Lung cancer is the leading cause of cancer deaths globally, with 20% of newly diagnosed lung cancers originating from the pulmonary neuroendocrine system [6]. - NENs are challenging due to their varied clinical features and aggressive nature, with carcinoid tumors having a 10-year survival rate of 58-83%, while neuroendocrine carcinomas have a much lower survival rate of 17% [6]. Liquid Biopsy Advantages - Liquid biopsy has gained traction as a diagnostic tool for pulmonary tumors due to its ease of access, quick turnaround time, and feasibility when tissue biopsies are not possible [8].
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN